Search Result

Results for "

Clindamycin hydrochloride

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (14) Bacterial (13) Biochemical Assay Reagents (3) Drug-Linker Conjugates for ADC (1) Isotope-Labeled Compounds (1) Parasite (9)
By Research Areas:	Cancer (6) Infection (14) Metabolic Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0408A

Clindamycin hydrochloride Maximum Cited Publications 7 Publications Verification	Bacterial Antibiotic	Infection Cancer
Clindamycin (hydrochloride) is a semisynthetic lincosamide antibiotic, which inhibits protein synthesis by acting on the 50S ribosomal.

HY-B1064

Clindamycin phosphate Maximum Cited Publications 7 Publications Verification Clindamycin 2-phosphate; U-28508	Bacterial Antibiotic Parasite	Infection
Clindamycin phosphate (Clindamycin 2-phosphate) is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate can be used for researching acne and bacterial vaginosis ^[3].Clindamycin phosphate has no cytotoxicity。 Combined with platelet rich fibrin (PRF), PRF-Clindamycin phosphate enhances antimicrobial properties .

HY-B1454

Clindamycin palmitate hydrochloride	Bacterial Antibiotic	Infection
Clindamycin palmitate hydrochloride is a hydrochloride salt of the ester of clindamycin and palmitic acid and it is an antibacterial agent. Clindamycin palmitate hydrochloride is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin .

HY-B0408AR

Clindamycin hydrochloride (Standard)	Bacterial Antibiotic	Infection Cancer
Clindamycin (hydrochloride) (Standard) is the analytical standard of Clindamycin (hydrochloride). This product is intended for research and analytical applications. Clindamycin (hydrochloride) is a semisynthetic lincosamide antibiotic, which inhibits protein synthesis by acting on the 50S ribosomal.

HY-N7118

Clindamycin hydrochloride monohydrate	Bacterial Antibiotic	Infection Cancer
Clindamycin hydrochloride monohydrate is an oral protein synthesis inhibitory agent that has the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin hydrochloride monohydrate resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin hydrochloride monohydrate decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla) .

HY-B1064A

Clindamycin phosphate hydrochloride Clindamycin 2-phosphate hydrochloride; U-28508 hydrochloride	Bacterial Antibiotic Parasite	Infection
Clindamycin phosphate (Clindamycin 2-phosphate) hydrochloride is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate hydrochloride is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate hydrochloride can be used for researching acne and bacterial vaginosis .

HY-B1064R

Clindamycin phosphate (Standard) Clindamycin 2-phosphate (Standard); U-28508 (Standard)	Bacterial Antibiotic Parasite	Infection
Clindamycin phosphate (Standard) is the analytical standard of Clindamycin phosphate. This product is intended for research and analytical applications. Clindamycin phosphate (Clindamycin 2-phosphate) is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate can be used for researching acne and bacterial vaginosis .

HY-B1454R

Clindamycin palmitate hydrochloride (Standard)	Bacterial Antibiotic	Infection
Clindamycin palmitate (hydrochloride) (Standard) is the analytical standard of Clindamycin palmitate (hydrochloride). This product is intended for research and analytical applications. Clindamycin palmitate hydrochloride is a hydrochloride salt of the ester of clindamycin and palmitic acid and it is an antibacterial agent. Clindamycin palmitate hydrochloride is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin .

HY-W777995

Clindamycin B	Antibiotic Bacterial Parasite	Infection
Clindamycin B is a derivative of Clindamycin (HY-B1455) .

HY-B1455R

Clindamycin (Standard)	Bacterial Antibiotic Parasite	Infection Cancer
Clindamycin (Standard) is the analytical standard of Clindamycin. This product is intended for research and analytical applications. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-B1455

*Clindamycin* Maximum Cited Publications 7 Publications Verification	Bacterial Antibiotic Parasite	Infection Cancer
Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria .

HY-B1455S

Clindamycin-d3 hydrochloride	Bacterial Antibiotic Parasite	Infection
Clindamycin-d₃ (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2].

HY-B1455S1

Clindamycin-13C,d3	Isotope-Labeled Compounds Bacterial Antibiotic Parasite	Infection
Clindamycin- ¹³C,d₃ is the ¹³C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2][3].

HY-127059

Clindamycin Sulfoxide U-25026A	Others	Metabolic Disease
Clindamycin sulfoxide is an active metabolite of the antibiotic Clindamycin (HY-B1455). It is formed via S-oxidation of clindamycin primarily by the cytochrome P450 (CYP) isoform CYP3A4. Clindamycin sulfoxide inhibits the growth of P. prevotti, B. fragilis, and C. sordelli in vitro with MIC values of 2, 2, and 1 mg/L, respectively.

HY-128907

MC-Val-Cit-PAB-clindamycin	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-PAB-clindamycin is a agent-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

HY-W704813

2,3,4-Tris-O-(trimethylsilyl) 7-epi clindamycin	Biochemical Assay Reagents	Others
2,3,4-Tris-O-(trimethylsilyl) 7-epi clindamycin is a biochemical reagent.

HY-163973

α-D-Glucopyranosyl β-D-arabino-2-hexulofuranosidonic acid	Biochemical Assay Reagents	Others
Clindamycin 2,4-diphosphate is a biochemical assay reagent.

HY-163967

Clindamycin 2,4-diphosphate	Biochemical Assay Reagents	Others
Arlacel A is a biochemical assay reagent.

HY-134914

Fosmidomycin	Antibiotic Parasite	Infection
Fosmidomycin is an orally active antibiotic, which exhibits antimalarial activity through inhibition of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DOXP reductoisomerase). Fosmidomycin inhibits P. falciparum strains 3D7, HB3, Dd2 and A2, with IC₅₀s of 150, 71, 170 and 150 ng/mL, respectively. Fosmidomycin exhibits synergistic effect with Clindamycin (HY-B1455), and ameliorates malaria in mouse model .

2,3,4-Tris-O-(trimethylsilyl) 7-epi clindamycin	Drug Delivery
2,3,4-Tris-O-(trimethylsilyl) 7-epi clindamycin is a biochemical reagent.

α-D-Glucopyranosyl β-D-arabino-2-hexulofuranosidonic acid	Carbohydrates
Clindamycin 2,4-diphosphate is a biochemical assay reagent.

Clindamycin 2,4-diphosphate	Cell Assay Reagents
Arlacel A is a biochemical assay reagent.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-134914

Fosmidomycin	Structural Classification Microorganisms Antibiotics Source classification Other Antibiotics	Antibiotic Parasite
Fosmidomycin is an orally active antibiotic, which exhibits antimalarial activity through inhibition of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DOXP reductoisomerase). Fosmidomycin inhibits P. falciparum strains 3D7, HB3, Dd2 and A2, with IC₅₀s of 150, 71, 170 and 150 ng/mL, respectively. Fosmidomycin exhibits synergistic effect with Clindamycin (HY-B1455), and ameliorates malaria in mouse model .

Cat. No.	Product Name	Chemical Structure

HY-B1455S1

Clindamycin-13C,d3
Clindamycin- ¹³C,d₃ is the ¹³C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2][3].

Clindamycin-13C,d3

Clindamycin- ¹³C,d₃ is the ¹³C- and deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2][3].

HY-B1455S

Clindamycin-d3 hydrochloride
Clindamycin-d₃ (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2].

Clindamycin-d3 hydrochloride

Clindamycin-d₃ (hydrochloride) is the deuterium labeled Clindamycin. Clindamycin is an orally active and broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin can inhibit bacterial protein synthesis, possessing the ability to suppress the expression of virulence factors in Staphylococcus aureus at sub-inhibitory concentrations (sub-MICs). Clindamycin resistance results from enzymatic methylation of the antibiotic binding site in the 50S ribosomal subunit (23S rRNA). Clindamycin decreases the production of Panton-Valentine leucocidin (PVL), toxic-shock-staphylococcal toxin (TSST-1) or alpha-haemolysin (Hla). Clindamycin also can be used for researching malaria[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks